Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Timing of Potassium Monitoring in Females Treated for Acne with Spironolactone is Not Optimal: A Retrospective Cohort Study
Description
In a retrospective cohort study led by Jenny Lie at Harvard Medical School, researchers examined the timing of potassium monitoring in females treated with spironolactone for acne. While potassium monitoring may not be necessary for younger, healthy patients, it remains essential for those with risk factors for hyperkalemia, yet only about one-third of patients were being monitored. The study utilized the MarketScan claims database from 2017 to 2020, focusing on female patients over 12 years old who were prescribed spironolactone. Key findings revealed that only 31% of patients had potassium monitoring, with higher rates observed in older age groups. Alarmingly, the average time until the first potassium assessment was 118 days, significantly beyond the recommended one-week timeframe, with only 5.5% receiving timely monitoring. The findings indicate a notable gap in clinical practice, suggesting an urgent need to optimize potassium monitoring protocols to improve patient safety and care quality. The researchers advocate for updated clinical guidelines addressing the timing of potassium checks in acne treatment with spironolactone, emphasizing that early detection of hyperkalemia can prevent serious complications.
View moreConclusions
- Potassium monitoring is only considered necessary for about one-third of patients treated with spironolactone for acne.
- Younger, healthy individuals generally have low usefulness for potassium monitoring when treated with spironolactone.
- Patients with additional risk factors for hyperkalemia may benefit from potassium monitoring during spironolactone treatment.
- The study found that the average time to first potassium measurement was 118 days after starting spironolactone.
- Only 5.5% of patients had potassium monitoring within the recommended time frame of one week after starting treatment.
- There is an opportunity to optimize potassium monitoring timing for patients using spironolactone for acne to align with clinical guidelines.
- Improving the timing of potassium monitoring can enhance patient care quality by enabling early detection of hyperkalemia.
- Future clinical practice guidelines should address the need for timely potassium monitoring in patients treated with spironolactone for acne.
- Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015;151(9):941-944. doi:10.1001/jamadermatol.2015.34
- Thiede RM, Rastogi S, Nardone B, et al. Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. Int J Womens Dermatol. 2019;5(3):155-157. Published 2019 Apr 25. doi:10.1016/j.ijwd.2019.04.024
- Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. doi:10.1016/j.jaad.2023.12.017
- ALDACTONE (spironolactone) full prescribing information. 2018. G.D. Searle LLC Division of Pfizer Inc.